TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05919108: Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Sponsor: Vanderbilt-Ingram Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,247,400

Rescue Site Savings

+$831,600

Unlock Full NCT05919108 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05919108 Rescue Dossier →